We will be attending the ESC Congress in Munich – which has developed into the world’s largest conference in cardiovascular medicine – this August 25-29th.
We invite you to visit us at our booth D450 and hear more about our options for cardiovascular diseases.
Join us for a discussion
Stop by for our poster session, hosted by Blueprint Genetics’ Chief Medical Officer and Laboratory Director Juha Koskenvuo (MD, PhD), as he presents the topic of JPH2 p.(Thr161Lys) – a Finnish founder mutation associating to hypertrophic cardiomyopathy with or without systolic heart failure and conduction abnormalities. Time: Tuesday 28th at 15:00-16:40, nro. 80542.
Additionally, welcome to meet Juha Koskenvuo on his Cardiology Q&A session where you are able to have a discussion on the latest updates about cardiovascular genetic testing. Time: Monday 27th and Tuesday 28th at 13-14pm.
Find out more information about ESC 2018 here and join the discussion #ESCCongress.
Interested to learn more about cardiovascular genetic testing?
Laboratory Director, Chief Medical Officer, co-founder of Blueprint Genetics (MD, Ph.D.)
Juha Koskenvuo is the Laboratory Director and Chief Medical Officer as well as the co-founder of Blueprint Genetics. He is responsible for supervising laboratory production and for designing new diagnostic tests. He has a MD-PhD from the University of Turku.
In 2006, he completed his fellowship program in clinical physiology and nuclear medicine. The following year, he became a docent. From 2007 to 2009, he joined the UCSF Cardiac Stem Cell Translational Development Program (California, USA) as a post-doctoral researcher and later as a research specialist.